Pharma Pipeline Intelligence MCP Server

Drug pipeline competitive intelligence and threat scoring for pharmaceutical companies, biotech investors, and medical affairs teams. This MCP server orchestrates 7 data sources spanning clinical trials, FDA/EMA regulatory databases, adverse event reporting, patent filings, and biomedical literature to produce Pipeline Threat Scores (0-100) with four specialized sub-models. Ask your AI assistant to analyze any drug, therapeutic area, or pharmaceutical company and receive structured competitive intelligence in seconds.

What data can you access?

Data Point	Source
Active clinical trials by phase, sponsor, enrollment	ClinicalTrials.gov
FDA drug approvals (NDA, BLA, ANDA)	openFDA
EMA marketing authorizations	European Medicines Agency
Adverse event reports (serious, deaths, hospitalizations)	FDA FAERS
Drug recalls and safety communications	FDA Enforcement
Patent filings, assignees, expiration dates	USPTO
Biomedical publication trends and citation velocity	PubMed

MCP Tools

Tool	Price	Description
search_drug_pipeline	$2.00	Search ClinicalTrials.gov for active trials by drug, condition, sponsor, phase, or status
analyze_competitive_landscape	$2.00	FDA approvals + EMA authorizations + active trials for a therapeutic area with Pipeline Threat Score
detect_adverse_event_signals	$2.00	Detect adverse event signal divergence from FDA FAERS data with statistical analysis
track_patent_exclusivity	$2.00	Track patent exclusivity windows, expiration dates, and first-mover advantage assessment
compare_regulatory_pathways	$2.00	Compare FDA vs EMA regulatory pathways and approval status for a drug or class
monitor_drug_recalls	$2.00	Monitor FDA drug recalls by class (I, II, III), manufacturer, and distribution pattern
assess_literature_momentum	$2.00	Analyze PubMed publication velocity, citation acceleration, and research momentum
generate_pipeline_threat_report	$5.00	Comprehensive pipeline threat report across all 7 sources with composite scoring

Data Sources

• Clinical Trial Tracker -- Live ClinicalTrials.gov study data including phases, enrollment, sponsors, and study status
• openFDA Drug Events -- FDA Adverse Event Reporting System (FAERS) with serious outcome classification
• FDA Drug Approvals -- NDA/BLA/ANDA approval data with dates, sponsors, and application types
• FDA Drug Recalls -- Drug recall enforcement actions with classification, distribution, and reason
• PubMed Search -- Biomedical literature search with publication dates, journals, and citation data
• USPTO Patent Search -- Pharmaceutical patent filings with assignees, claims, and expiration dates
• EMA Medicines -- European Medicines Agency authorized product data and marketing authorization status

How the scoring works

The MCP produces four scoring dimensions that combine into a composite Pipeline Threat Score (0-100):

Pipeline Threat Score evaluates competitive threat level based on Phase 3 trial density in the therapeutic area, recent FDA/EMA approvals for the same indication, adverse event signals for competitor drugs, and patent cliff proximity. Higher scores indicate greater competitive pressure.

First-Mover Advantage Index assesses time-to-market advantage by comparing trial phase progression against competitors and mapping patent exclusivity windows. Incorporates patent portfolio breadth and earliest expiration dates to estimate years of remaining exclusivity.

Adverse Event Signal Divergence detects statistically unusual adverse event patterns versus the background rate. Analyzes serious events, deaths, and hospitalizations from FAERS data to identify safety signals that could impact a drug's competitive position.

Literature Momentum Score measures publication velocity and citation acceleration in a therapeutic area. Rapid publication growth signals increasing research interest, which often precedes new entrants and competitive activity.

Score Range	Threat Level	Interpretation
0-25	Low Threat	Limited competitive activity, strong defensive position
26-50	Moderate Threat	Some competitive activity, monitor developments
51-75	High Threat	Active competitor pipeline, strategic response needed
76-100	Critical Threat	Dense competition, patent cliffs, or safety signals

How to connect this MCP server

Claude Desktop

Add to your claude_desktop_config.json:

{
  "mcpServers": {
    "pharma-pipeline": {
      "url": "https://pharma-pipeline-intelligence-mcp.apify.actor/mcp"
    }
  }
}

Programmatic (HTTP)

curl -X POST https://pharma-pipeline-intelligence-mcp.apify.actor/mcp \
  -H "Content-Type: application/json" \
  -H "Authorization: Bearer YOUR_APIFY_TOKEN" \
  -d '{"jsonrpc":"2.0","method":"tools/call","params":{"name":"analyze_competitive_landscape","arguments":{"query":"GLP-1 agonist obesity"}},"id":1}'

This MCP also works with Cursor, Windsurf, Cline, and any other MCP-compatible client.

Use cases for pharmaceutical pipeline intelligence

Competitive Landscape Monitoring for Business Development

Identify all FDA/EMA-approved products and active trials in a therapeutic area to inform licensing, co-development, and partnership decisions with quantified competitive density.

Biotech Investment Thesis Validation

Score pipeline risk for pre-IPO or clinical-stage biotech companies by analyzing trial phase distribution, adverse event signals, and patent protection strength before committing capital.

Patent Cliff and Generic Entry Risk Assessment

Track patent exclusivity windows and upcoming expirations for branded drugs. Identify generic entry timing windows and assess first-mover advantage for biosimilar or generic strategies.

Safety Signal Surveillance for Medical Affairs

Detect emerging adverse event signal divergence from FAERS data to support pharmacovigilance activities. Identify safety signals early before they impact regulatory or commercial outcomes.

Literature Momentum Tracking for Research Strategy

Monitor PubMed publication acceleration in emerging therapeutic areas to identify research trends that may signal competitive threats or opportunities for early positioning.

Regulatory Pathway Comparison for Market Access

Compare FDA and EMA regulatory approaches for a drug class to identify regulatory gaps, predict approval timeline differences, and plan global launch sequencing.

How much does it cost?

This MCP uses pay-per-event pricing. You are only charged when a tool is called -- there is no subscription or minimum commitment.

The Apify Free plan includes $5 of monthly platform credits, which covers 2 full pipeline threat reports or several individual tool calls.

Example Use	Approximate Cost
Search clinical trials for a drug	$2.00
Full competitive landscape analysis	$2.00
Comprehensive pipeline threat report (all 7 sources)	$5.00
Monthly monitoring of 3 therapeutic areas	~$18.00

How it works

1. You call a tool via any MCP client (Claude Desktop, Cursor, programmatic HTTP)
2. The MCP server runs Apify actors in parallel -- up to 7 actors simultaneously for the comprehensive report
3. Scoring algorithms process the results -- Pipeline Threat Score, First-Mover Advantage, Adverse Event Divergence, and Literature Momentum are computed from the combined data
4. Structured JSON is returned via the MCP protocol with scores, signals, and supporting data

For the generate_pipeline_threat_report tool, all 7 actors run in parallel: ClinicalTrials.gov, openFDA adverse events, FDA approvals, FDA recalls, PubMed, USPTO patents, and EMA medicines. Results are combined into a composite report with the company and drug context you specify.

FAQ

Q: How current is the clinical trial data? A: Clinical trial data is fetched live from ClinicalTrials.gov, which is updated by sponsors. There may be a lag of days to weeks depending on sponsor reporting frequency.

Q: Does this replace pharmacovigilance systems? A: No. This provides signal detection from public FDA FAERS data. It complements but does not replace enterprise pharmacovigilance systems or CIOMS-compliant safety databases.

Q: Can I track a specific drug over time? A: Yes. Call the same tools periodically (weekly or monthly) and compare scores over time to detect changes in competitive positioning, safety signals, or research momentum.

Q: What about non-US regulatory data? A: The MCP includes EMA (European Medicines Agency) data alongside FDA data. The compare_regulatory_pathways tool specifically enables FDA vs EMA comparison.

Q: Is it legal to use this data? A: All data sources are public databases operated by government agencies (FDA, NIH, USPTO, EMA). See Apify's guide on web scraping legality.

Q: Can I combine this with other MCPs? A: Yes. Use this alongside the Product Safety Consumer Risk MCP for consumer health products or the Research Integrity Screening MCP for academic publication quality assessment.

Related MCP servers

MCP Server	Description
ryanclinton/product-safety-consumer-risk-mcp	Consumer product safety and recall intelligence
ryanclinton/research-integrity-screening-mcp	Academic fraud and publication quality screening
ryanclinton/food-safety-supply-chain-mcp	Food safety and supply chain risk monitoring

Integrations

This MCP server is built on the Apify platform and supports:

• Apify API for programmatic access and automation
• Scheduled runs via Apify Scheduler for recurring competitive monitoring
• Webhooks for triggering downstream workflows when new intelligence is available
• Integration with 200+ Apify actors for extending data coverage